Ajit directs Cambridge Wide Open Week and handles marketing and PR at o2h Ventures. He brings extensive marketing and ecosystem experience from his time across the o2h group and digital agencies.
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
Mercia Ventures led the seed financing round with participation from several backers to support platform validation and team growth.
"Enzymes play a wide-ranging role in disease, but current technologies are unable to develop drugs to tackle most of them. Our team at Kuano recognised the need to overcome these limitations."
MP Healthcare led the pre-Series A financing to help fund the expansion of the company drug discovery pipeline in oncology and neurology.
"At PharmEnable, we believe that everyone deserves safe and effective treatments, and we are committed to applying the principles chemical novelty, diversity and 3-dimensionality to design powerful new small molecule drugs."
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
"This latest funding will enable us to build on and accelerate our successful computational design-led discovery focus. We are excited to be playing a pivotal role in the innovation of oncological treatments leading to better outcomes for cancer patients worldwide. Our groundbreaking new approach stands to be initially validated by the proof-of-concept studies. We are achieving rapid progress not only with our industry-leading drug discovery programme, but also our proprietary AI platform. This has led to increasing interest from third parties in our machine learning capabilities, so we are keen to capitalise on this demand and establish a commercial effort in this area"
The funding round was led by Heal Capital and will support team expansion and product development.
"Healthcare touches each and every one of us and the recent pandemic has highlighted that at a global level. It showed the need to bring healthcare closer to people’s homes and that we need to leverage many of the recent innovations in digital health and consumer biotech to capture as many data points about human health as possible. This will transform our understanding of the human body and our approach to disease detection and management. At Sanome we are working toward developing multiple at home health tools to drive disruption within the healthcare landscape to benefit each one of us"
